Intravitreal triamcinolone improves recovery of visual acuity in nonarteritic anterior ischemic optic neuropathy

Journal of Neuro-Ophthalmology

Volumn 27, Issue 3, 2007, Pages 164-168

  Kaderli, Berkant ^a   Avci, Remzi ^a   Yucel, Ali ^a   Guler, Kazim ^b   Gelisken, Oner ^a  

^a ULUDAG UNIVERSITY   (Turkey)

^b Focus Laser Eye Center   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; TRIAMCINOLONE;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; ISCHEMIC OPTIC NEUROPATHY; MALE; NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY; PAPILLEDEMA; PILOT STUDY; PRIORITY JOURNAL; VISUAL ACUITY; VISUAL FIELD; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

AGED; ANTI-INFLAMMATORY AGENTS; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; OPTIC DISK; OPTIC NERVE; OPTIC NEURITIS; OPTIC NEUROPATHY, ISCHEMIC; PAPILLEDEMA; PILOT PROJECTS; RECOVERY OF FUNCTION; RETINAL ARTERY; TREATMENT OUTCOME; TRIAMCINOLONE; VISUAL ACUITY;

EID: 34748860926     PISSN: 10708022     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNO.0b013e31814a5a9a     Document Type: Article

References (16)

1. The Ischemic Optic Neuropathy Decompression Trial Study Group. Characteristics of patients with nonarteritic ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch Ophthalmol 1996;114:1366-74.
2. The Ischemic Optic Neuropathy Decompression Trial Research Group. Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. JAMA 1995;273:625-32.
3. Colen TP, van Everdingen JA, Lemij HG. Axonal loss in a patient with anterior ischemic optic neuropathy as measured by scanning laser polarimetry. Am J Ophthalmol 2000;130:847-50.
4. McLeod D, Marshall J, Kohner EM. Role of axoplasmic transport in the pathophysiology of ischaemic disc swelling. Br J Ophthalmol 1980;64:247-61.
5. Al-Haddad CE, Jurdi FA, Bashshur ZF. Intravitreal triamcinolone acetonide for the management of diabetic papillopathy. Am J Ophthalmol 2004;137:1151-3.
6. Ischemic Optic Neuropathy Decompression Trial: twenty-four-month update. Arch Ophthalmol 2000;118:793-8.
7. Arnold AC. Ischemic optic neuropathy, diabetic papillopathy, and papillophlebitis. In: Yanoff M, Duker JS, eds. Ophthalmology. London: Mosby; 1999:11.7.1-11.7.6.
8. Savino PJ, Danesh-Meyer H. Neuro-Ophthalmology: Color Atlas and Synopsis of Clinical Ophthalmology. New York: McGraw-Hill, 2003.
9. Arnold AC, Levin LA. Treatment of ischemic optic neuropathy. Semin Ophthalmol 2002;17:39-46.
10. Knox DL, Kerrison JB, Green WR. Histopathologic studies of ischemic optic neuropathy. Trans Am Ophthalmol Soc 2000;98:203-20.
11. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res 2005;24:587-611.
12. Jonas JB, Spandau UH, Harder B, et al. Intravitreal triamcinolone acetonide for treatment of acute nonarteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2007;245:749-750.
13. Jonas JB. Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 2004;137:560-2.
14. Mason JO 3rd, Somaiya MD, Singh RJ. Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes. Retina 2004;24:900-4.
15. Avci R, Kaderli B, Akalp FD. Intravitreal triamcinolone injection for chronic diffuse diabetic macular oedema. Clin Experiment Ophthalmol 2006;34:27-32.
16. Shields CL, Demirci H, Marr BP, et al. Intravitreal triamcinolone acetonide for acute radiation papillopathy. Retina 2006;26:537-44.